Accredited Co-developed Learning Activities

Pre- Registration Not Required, all welcome

Thursday, April 11, 2024

}

10:30 – 11:30

North Tower

- Grand Ballroom BC

Respiratory Syncytial Virus (RSV) Burden of Disease in Infants – A Need for All Infant Protection

(co-developed learning activity)

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Sanofi and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.

Friday, April 12, 2024

}

14:00 – 15:00

North Tower

- Grand Ballroom BC

Vaccines for Those with Compromised Immune Function Due to Aging and Comorbidities

(co-developed learning activity)

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and GSK and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.

Pre-Registration Required to a maximum of 150 participants

  • No walks in will be permitted once maximum is reached
  • No industry participants re permitted to attend, other than those from the co-developing company

Wednesday, April 10, 2024

}

11:30 – 12:30

North Tower

- Grand Ballroom A

Changing Resistance Epidemiology of Gram-negative Pathogens:
Are Current Empiric Antibiotic Choices Adequate?

(co-developed learning activity, pre-registration required to maximum of 150 participants)

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Merck Canada and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.

}

11:30 – 12:30

North Tower

- Grand Ballroom D

Long-Acting Lipoglycopeptides: Where Do They Fit in the Contemporary Treatment of Infections?

(co-developed learning activity, pre-registration required to maximum of 150 participants)

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Paladin and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.

Thursday, April 11, 2024

}

16:00 – 17:00

North Tower

- Grand Ballroom A

Increasing Cervical Cancer Prevention Worldwide

(co-developed learning activity, pre-registration required to maximum of 150 participants)

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Hologic and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.

}

16:00 – 17:00

North Tower

- Grand Ballroom D

Adapting to the Times: Vaccination’s Crucial Role in RSV, Flu, COVID-19, and Pneumococcal Disease

(co-developed learning activity, pre-registration required to maximum of 150 participants)

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Pfizer Canada and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.

Friday, April 12, 2024

}

11:30 – 12:30

North Tower

- Grand Ballroom A

Adult-designed Vaccines – A Paradigm Shift Long Overdue

(co-developed learning activity, pre-registration required to maximum of 150 participants)

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Merck Canada and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.

}

11:30 – 12:30

North Tower

- Grand Ballroom D

HPV Primary Screening Implementation in British Columbia: From the Clinical Perspective and Laboratory Perspective

(co-developed learning activity, pre-registration required to maximum of 150 participants)

This educational event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by AMMI Canada. The program was co-developed with AMMI Canada and Roche and was planned to achieve scientific integrity, objectivity, and balance.
Under the guidance of the Innovative Medicines Canada Code of Ethical Practices this event is for healthcare professionals only.